Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required)

Funding Opportunity RFA-DA-24-024 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to use multidisciplinary approaches to advance basic and clinical research and address key knowledge gaps on psychedelics. Given the therapeutic promise that psychedelics hold as neurotherapeutics, the goal is to systematically evaluate, and understand their mechanism of action and drug-target engagement, along with other translational aspects including their safety, pharmacokinetics/pharmacodynamics, and efficacy, in the context of substance use disorders (SUD).